Printer Friendly

CELGENE ENTERS RESEARCH AND DEVELOPMENT AGREEMENT WITH ROCKEFELLER UNIVERSITY

 CELGENE ENTERS RESEARCH AND DEVELOPMENT
 AGREEMENT WITH ROCKEFELLER UNIVERSITY
 WARREN, N.J., Aug. 3 /PRNewswire/ -- Celgene Corporation (NASDAQ: CELG) today announced that it has entered into a research and development agreement with The Rockefeller University to prove the effectiveness of certain chiral glutarimides and their derivatives in reducing symptoms associated with elevated Tumor Necrosis Factor (TNFa) levels in patients.
 Under terms of the two-year agreement, Celgene and The Rockefeller University will collaborate to determine the selective immunomodulatory properties and mechanisms of the compounds and to expedite promising candidates into clinical trials. Celgene will receive exclusive manufacturing and marketing rights to any drugs resulting from the research.
 "Celgene's long-term chiral products strategy is to leverage its expertise in development and chiral intermediates into the area of proprietary products," said John Ufheil, president and chief executive officer. "As we have stated previously, given success at the early stages, we plan to ally with interested pharmaceutical companies to commercialize such products."
 As the program advances, the compounds might lead to a series of drugs which would reduce or eliminate the catastrophic inflammatory response and subsequent debilitation or death associated with TNFa production in a wide range of diseases such as tuberculosis and septic shock.
 The Rockefeller University has begun limited clinical trials on its first compound. IND status was awarded based on results arising out of studies where the first compound was shown effective in alleviating fever and cachexia in response to tubercular infection. A broad patent application has been filed. Results of the initial clinical trials will not be available until 1993.
 Celgene's role will be to identify and synthesize key bioactive chiral molecules for clinical evaluation by Rockefeller and determine the chemistry of their metabolism.
 Professor Gilla Kaplan, Laboratory of Cellular Physiology and Immunology, will lead the research effort at The Rockefeller University,.
 The Rockefeller University was founded in 1901 by John D. Rockefeller as the nation's first biomedical research center. A world leader in science and education, it has been at the forefront of many of the major scientific discoveries of the 20th Century. Nineteen Nobel laureates have been associated with the university, five of whom are on campus today.
 Celgene Corporation, based in Warren, is a chemical biotechnology company engaged in the development and commercialization of new biocatalytic products and systems including chiral compounds for the pharmaceutical industry and process biotreatment systems.
 -0- 8/3/92
 /CONTACT: Sol J. Barer of Celgene, 908-271-4153, or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for Celgene/
 (CELG) CO: Celgene Corporation; The Rockefeller University ST: New Jersey IN: HEA SU:


SM-TS -- NY016 -- 6039 08/03/92 10:09 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 3, 1992
Words:437
Previous Article:HOME SHOPPING NETWORK COMPLETES PSi SPIN-OFF
Next Article:IRT PROPERTY COMPANY COMPLETES ACQUISITION OF $87 MILLION SHOPPING CENTER PORTFOLIO -- ACQUIRES THOMASVILLE, N.C., K-MART CENTER
Topics:


Related Articles
OLD DRUG SHOWS NEW PROMISE IN AIDS TREATMENT
THALIDOMIDE ENTERS PHASE II STUDY FOR MAJOR AIDS CONDITION AT TWO CENTERS; CELGENE EXPECTS RESULTS IN SIX MONTHS
THALIDOMIDE ENTERS PHASE II STUDY FOR MAJOR AIDS CONDITION AT TWO CENTERS; CELGENE EXPECTS RESULTS IN SIX MONTHS
CELGENE GAINS EXCLUSIVE RIGHTS TO THALIDOMIDE UNDER ROCKEFELLER PATENT
U.S. GOVERNMENT BEGINS TESTING CELGENE'S THALIDOMIDE IN HIV INFECTED PATIENTS
CELGENE CORPORATION'S SYNOVIR IN CLINICAL TEST FOR RHEUMATOID ARTHRITIS
NEW THALIDOMIDE ANALOGS PROMISE MORE POTENT, POTENTIALLY SAFER DRUGS FOR CONTROLLING INFLAMMATORY DISEASE
American Chemical Society Reports on New Category of Anti-Inflammatory Drugs Derived from Thalidomide
Celgene Corporation Announces Two Exclusive Worldwide Licenses For Major New Class of Drug Targets.
Universities share technologies to fight hunger.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters